Journal of International Oncology ›› 2022, Vol. 49 ›› Issue (11): 696-609.doi: 10.3760/cma.j.cn371439-20220507-00137
• Reviews • Previous Articles Next Articles
Xu Xi1, Gao Hongliang1, Liu Xiang2, Zhang Zhensheng1(), Xu Chuanliang1
Received:
2022-05-07
Revised:
2022-05-26
Online:
2022-11-08
Published:
2022-12-06
Contact:
Zhang Zhensheng
E-mail:13761178177@163.com
Supported by:
Xu Xi, Gao Hongliang, Liu Xiang, Zhang Zhensheng, Xu Chuanliang. Correlations between different pH values in tumor microenvironment and bladder cancer[J]. Journal of International Oncology, 2022, 49(11): 696-609.
[1] |
Teoh JY, Huang J, Ko WY, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita[J]. Eur Urol, 2020, 78(6): 893-906. DOI: 10.1016/j.eururo.2020.09.006.
doi: 10.1016/j.eururo.2020.09.006 |
[2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. DOI: 10.3322/caac.21332.
doi: 10.3322/caac.21332 |
[3] |
Lieske JC, Turner ST, Edeh SN, et al. Heritability of urinary traits that contribute to nephrolithiasis[J]. Clin J Am Soc Nephrol, 2014, 9(5): 943-950. DOI: 10.2215/CJN.08210813.
doi: 10.2215/CJN.08210813 |
[4] |
Asgharzadeh MR, Barar J, Pourseif MM, et al. Molecular machine-ries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy[J]. Bioimpacts, 2017, 7(2): 115-133. DOI: 10.15171/bi.2017.15.
doi: 10.15171/bi.2017.15 pmid: 28752076 |
[5] |
Kamphuis GM, Wouter van Hattum J, de Bie P, et al. Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review[J]. Transl Androl Urol, 2019, 8(Suppl 4): S448-S456. DOI: 10.21037/tau.2019.05.01.
doi: 10.21037/tau.2019.05.01 |
[6] |
Heer F, Dobenecker B, Kienzle E. Effect of cation-anion balance in feed on urine pH in rabbits in comparison with other species[J]. J Anim Physiol Anim Nutr (Berl), 2017, 101(6): 1324-1330. DOI: 10.1111/jpn.12653.
doi: 10.1111/jpn.12653 |
[7] |
Böswald LF, Matzek D, Kienzle E, et al. Influence of strain and diet on urinary pH in laboratory mice[J]. Animals (Basel), 2021, 11(3): 702. DOI: 10.3390/ani11030702.
doi: 10.3390/ani11030702 |
[8] |
Worcester EM, Bergsland KJ, Gillen DL, et al. Mechanism for higher urine pH in normal women compared with men[J]. Am J Physiol Renal Physiol, 2018, 314(4): F623-F629. DOI: 10.1152/ajprenal.00494.2017.
doi: 10.1152/ajprenal.00494.2017 |
[9] |
Seisen T, Granger B, Colin P, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma[J]. Eur Urol, 2015, 67(6): 1122-1133. DOI: 10.1016/j.eururo.2014.11.035.
doi: S0302-2838(14)01218-4 pmid: 25488681 |
[10] |
Tsai MJ, Chang WA, Huang MS, et al. Tumor microenvironment: a new treatment target for cancer[J]. ISRN Biochem, 2014, 2014: 351959. DOI: 10.1155/2014/351959.
doi: 10.1155/2014/351959 |
[11] |
Xie R, Wang H, Jin H, et al. NHE1 is upregulated in gastric cancer and regulates gastric cancer cell proliferation, migration and invasion[J]. Oncol Rep, 2017, 37(3): 1451-1460. DOI: 10.3892/or.2017.5386.
doi: 10.3892/or.2017.5386 pmid: 28098891 |
[12] |
Chan JCY, Diakos CI, Engel A, et al. Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer[J]. PLoS One, 2020, 15(1): e0228466. DOI: 10.1371/journal.pone.0228466.
doi: 10.1371/journal.pone.0228466 |
[13] |
Hamaguchi R, Narui R, Wada H. Effects of alkalization therapy on chemotherapy outcomes in metastatic or recurrent pancreatic cancer[J]. Anticancer Res, 2020, 40(2): 873-880. DOI: 10.21873/anticanres.14020.
doi: 10.21873/anticanres.14020 pmid: 32014931 |
[14] |
Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy[J]. Cancer Res, 2016, 76(6): 1381-1390. DOI: 10.1158/0008-5472.CAN-15-1743.
doi: 10.1158/0008-5472.CAN-15-1743 pmid: 26719539 |
[15] |
Ibrahim-Hashim A, Estrella V. Acidosis and cancer: from mechanism to neutralization[J]. Cancer Metastasis Rev, 2019, 38(1/2):149-155. DOI: 10.1007/s10555-019-09787-4.
doi: 10.1007/s10555-019-09787-4 |
[16] |
Ando H, Emam SE, Kawaguchi Y, et al. Increasing tumor extracellular pH by an oral alkalinizing agent improves antitumor responses of anti-PD-1 antibody: implication of relationships between serum bicarbonate concentrations, urinary pH, and therapeutic outcomes[J]. Biol Pharm Bull, 2021, 44(6): 844-852. DOI: 10.1248/bpb.b21-00076.
doi: 10.1248/bpb.b21-00076 pmid: 34078817 |
[17] |
Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of micro-environment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes[J]. Cancer Res, 2012, 72(11): 2746-2756. DOI: 10.1158/0008-5472.CAN-11-1272.
doi: 10.1158/0008-5472.CAN-11-1272 pmid: 22593198 |
[18] |
Kolosenko I, Avnet S, Baldini N, et al. Therapeutic implications of tumor interstitial acidification[J]. Semin Cancer Biol, 2017, 43: 119-133. DOI: 10.1016/j.semcancer.2017.01.008.
doi: S1044-579X(17)30016-0 pmid: 28188829 |
[19] |
Demirbas A, Sarici H, Kilinc MF, et al. The relationship between acidic urinary pH and overactive bladder; alkalization of urine improves the symptoms of overactive bladder[J]. Urol Int, 2015, 95(2): 223-226. DOI: 10.1159/000375322.
doi: 10.1159/000375322 pmid: 25766740 |
[20] |
Ceylan C, Doluoglu OG, Yahşi S. A different perspective: can urine pH be important in the diagnosis of prostate cancer?[J]. Urologia, 2020, 87(1): 19-22. DOI: 10.1177/0391560319865724.
doi: 10.1177/0391560319865724 pmid: 31364489 |
[21] |
Kondo A, Yamamoto S, Nakaki R, et al. Extracellular acidic pH activates the sterol regulatory element-binding protein 2 to promote tumor progression[J]. Cell Rep, 2017, 18(9): 2228-2242. DOI: 10.1016/j.celrep.2017.02.006.
doi: S2211-1247(17)30171-7 pmid: 28249167 |
[22] |
Xue L, Qi H, Zhang H, et al. Targeting SREBP-2-regulated mevalonate metabolism for cancer therapy[J]. Front Oncol, 2020, 10: 1510. DOI: 10.3389/fonc.2020.01510.
doi: 10.3389/fonc.2020.01510 pmid: 32974183 |
[23] |
Burgess EF, Livasy C, Trufan S, et al. Clinical outcomes asso-ciated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer[J]. Mol Clin Oncol, 2022, 16(5): 102. DOI: 10.3892/mco.2022.2535.
doi: 10.3892/mco.2022.2535 pmid: 35463214 |
[24] |
Andrade DL, Moretti TBC, Neto WA, et al. Smoke load prognostic impact on bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer[J]. Int Urol Nephrol, 2020, 52(8): 1471-1476. DOI: 10.1007/s11255-020-02438-6.
doi: 10.1007/s11255-020-02438-6 pmid: 32157620 |
[25] |
Zhao X, Wang Y, Liang C. Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis[J]. Int Urol Nephrol, 2022, 54(6): 1169-1185. DOI: 10.1007/s11255-022-03173-w.
doi: 10.1007/s11255-022-03173-w |
[26] |
Alguacil J, Kogevinas M, Silverman DT, et al. Urinary pH, cigarette smoking and bladder cancer risk[J]. Carcinogenesis, 2011, 32(6): 843-847. DOI: 10.1093/carcin/bgr048.
doi: 10.1093/carcin/bgr048 pmid: 21402590 |
[27] |
Ide H, Kikuchi E, Ogihara K, et al. Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history[J]. Sci Rep, 2021, 11(1): 20675. DOI: 10.1038/s41598-021-00184-y.
doi: 10.1038/s41598-021-00184-y pmid: 34667220 |
[28] |
Ogihara K, Kikuchi E, Yuge K, et al. Refraining from smoking for 15 years or more reduced the risk of tumor recurrence in non-muscle invasive bladder cancer patients[J]. Ann Surg Oncol, 2016, 23(5): 1752-1759. DOI: 10.1245/s10434-015-5016-z.
doi: 10.1245/s10434-015-5016-z |
[29] |
Ide H, Kikuchi E, Hagiwara M, et al. Urinary pH levels are strongly associated with bladder recurrence after nephroureterectomy in upper tract urothelial carcinoma patients with a smoking history[J]. Ann Surg Oncol, 2016, 23(Suppl 5): 1029-1038. DOI: 10.1245/s10434-016-5555-y.
doi: 10.1245/s10434-016-5555-y pmid: 27613550 |
[30] |
González-Padilla DA, Subiela JD, González-Díaz A, et al. Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: a retrospective cohort from a high-volume center[J]. Urol Oncol, 2022, 40(7): 345. e19-345.e23. DOI: 10.1016/j.urolonc.2022.02.018.
doi: 10.1016/j.urolonc.2022.02.018 |
[31] |
Maeda T, Kikuchi E, Matsumoto K, et al. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor[J]. J Urol, 2011, 185(3): 802-806. DOI: 10.1016/j.juro.2010.10.081.
doi: 10.1016/j.juro.2010.10.081 pmid: 21239010 |
[32] |
Miyata Y, Tsurusaki T, Hayashida Y, et al. Intravesical mitomycin C (MMC) and MMC+ cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial[J]. BJU Int, 2022, 129(4): 534-541. DOI: 10.1111/bju.15571.
doi: 10.1111/bju.15571 |
[33] |
Seo HK, Kim SH, Ahn KO, et al. Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients[J]. Oncotarget, 2017, 8(56): 96117-96125. DOI: 10.18632/oncotarget.21755.
doi: 10.18632/oncotarget.21755 pmid: 29221191 |
[34] |
Witjes JA, Palou J, Soloway M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)[J]. BJU Int, 2013, 112(6): 742-750. DOI: 10.1111/bju.12012.
doi: 10.1111/bju.12012 pmid: 23452187 |
[35] |
Stone BV, Ayangbesan A, Taylor BL, et al. Urinary pH and the risk of recurrence in patients with non-muscle invasive bladder cancer[J]. Can J Urol, 2018, 25(4): 9407-9412.
pmid: 30125520 |
[36] |
周邓婧, 姚颐, 宋启斌, 等. 肿瘤细胞对肿瘤微环境的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 424-428. DOI: 10.3760/cma.j.cn371439-20201216-00081.
doi: 10.3760/cma.j.cn371439-20201216-00081 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[4] | Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[5] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[6] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[7] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[8] | Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[9] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[10] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297. |
[11] | Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311. |
[12] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[13] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[14] | Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216. |
[15] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||